Regulatory Science as a Bridge Between Science and Society

Development of innovative drugs has recently become more difficult. The case of rosiglitazone shows the extreme difficulty of making the regulatory decision that will best balance the benefits and risks of a drug. There is a high expectation that regulatory science (RS) can improve the situation. However, without user understanding of its basic characteristics, RS will not deliver what is expected.

[1]  M. Joseph.  THALIDOMIDE AND CONGENITAL ABNORMALITIES , 1962, Developmental medicine and child neurology.

[2]  E. Antman,et al.  Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. , 2003, Journal of the American College of Cardiology.

[3]  M. Hamburg,et al.  Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. , 2010, The New England journal of medicine.

[4]  J. Caro,et al.  Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  P. A. de Graeff,et al.  Rosiglitazone: a European regulatory perspective , 2011, Diabetologia.

[6]  Lawrence D. Phillips,et al.  Benefit-risk methodology project: work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment , 2011 .

[7]  S. Yusuf,et al.  Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. , 2006, American heart journal.

[8]  J. Deckers,et al.  Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarction. , 2001, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[9]  J. Ware,et al.  Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.

[10]  Y. Uyama,et al.  Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity‐Related Drug Response Factors , 2010, Clinical pharmacology and therapeutics.